Exelixis' Cabozantinib Gets Breakthrough Therapy Status In Differentiated Thyroid Cancer

by Vandana Singh, Benzinga Editor

February 25, 2021 11:11 AM | 1 min read | Make a Comment

The FDA has granted Breakthrough Therapy Designation to Exelixis Inc's (NASDAQ: EXEL) CABOMETYX cabozantinib as a potential treatment for patients with differentiated thyroid cancer progressed following prior therapy and are radioactive iodine-refractory.
The company plans to submit a supplemental marketing application for the indication this year.
The planned interim analysis of the Phase 3 COSMIC-311 trial demonstrated a significant reduction in the risk of disease progression or death of 78% with cabozantinib versus placebo, thyroid cancer.
Price Action: EXEL shares are down 1.85% at $22.24 on the last check Thursday.

Posted In: Biotech News FDA General FDA Breakthrough Designation Thyroid Cancer

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.